Close this search box.

Clinical Trial: SWOG S1937

SWOG S1937

Status: Open

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Eligible for screening study DCP 001

S1937 , Arms 1 & 3  are reopened with the implementation of Revision 3 effective February 20, 2024.  

S1937, Arm 2 is closed to accrual, effective February 15, 2024.